SCORE

78

NBIX: Neurocrine Biosciences Inc. is a Buy


The current rating for NBIX is 78, which is 56% above its historic median rating of 50. This indicates lower risk than normal.


The rating is currently showing a higher than normal reading, suggesting risk levels could be lower than normal.